Short Interest in Cellebrite DI Ltd. (NASDAQ:CLBT) Grows By 13.6%

Cellebrite DI Ltd. (NASDAQ:CLBT) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 1,170,000 shares, an increase of 13.6% from the December 15th total of 1,030,000 shares. Approximately 1.4% of the shares of the stock are short sold. Based on an average trading volume of 1,310,000 shares, the short-interest ratio is presently 0.9 days.

Cellebrite DI Trading Down 0.9 %

Shares of NASDAQ:CLBT traded down $0.20 during trading on Friday, reaching $22.78. 1,221,391 shares of the company traded hands, compared to its average volume of 879,357. Cellebrite DI has a 52-week low of $8.23 and a 52-week high of $23.50. The firm has a market capitalization of $4.69 billion, a price-to-earnings ratio of -14.70, a P/E/G ratio of 3.18 and a beta of 1.46. The business’s fifty day moving average is $20.76 and its 200-day moving average is $17.60.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $106.90 million during the quarter, compared to analyst estimates of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The firm’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.09 EPS. On average, sell-side analysts predict that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have issued reports on CLBT shares. TD Cowen lifted their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Monday, September 23rd. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $22.00 to $24.00 and gave the company an “overweight” rating in a research report on Monday, December 16th. Needham & Company LLC boosted their price objective on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Craig Hallum upped their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $20.57.

Institutional Trading of Cellebrite DI

Several large investors have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. raised its position in Cellebrite DI by 59.6% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 2,724 shares of the company’s stock valued at $33,000 after purchasing an additional 1,017 shares during the last quarter. Tower View Wealth Management LLC raised its holdings in shares of Cellebrite DI by 1.2% during the third quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company’s stock valued at $2,200,000 after acquiring an additional 1,500 shares in the last quarter. Quarry LP purchased a new stake in Cellebrite DI in the third quarter worth $27,000. Advisors Asset Management Inc. boosted its holdings in Cellebrite DI by 130.5% in the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after acquiring an additional 1,742 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in Cellebrite DI by 28.6% during the 3rd quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock valued at $152,000 after purchasing an additional 2,000 shares during the period. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.